Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04511-0Source: DataRank Database

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies is a research paper published in Cancer Chemotherapy and Pharmacology (2023). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 1.73)OA: greenTopics (41)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Amanda Kagan ORCID,Michelle A. Rudek ORCID,Maciej Kmieciak ORCID,Mary Beth Tombes,Ellen Shrader

Live enrichment

PubMed:36864346 PMC:PMC10807611 OpenAlex:https://openalex.org/W4322764362

National Institutes of Health

Grant: UH2TR001373

National Institutes of Health

Grant: P30CA006973

National Institutes of Health

Grant: UL1TR003098

National Institutes of Health

Grant: S10OD020091

National Institutes of Health

Grant: Massey CCSG P30 CA016059

National Institutes of Health Experimental Therapeutics Clinical Trials Network

Grant: UM1CA186644

National Institutes of Health Experimental Therapeutics Clinical Trials Network

Grant: U24CA247648

National Institutes of Health Clinical Pharmacology Training Grant

Grant: T32GM066691

NCI NIH HHS

Grant: P30 CA016059

National Institutes of Health

Grant: 4P30CA016059-35

Massey Cancer Center Support Grant

National Institutes of Health

Grant: 5U24CA247648-04

The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN

National Institutes of Health

Grant: 5UL1TR003098-02

Johns Hopkins Institute for Clinical and Translational Research

National Institutes of Health

Grant: 5T32GM066691-18

Clinical Pharmacology Training Program

National Institutes of Health

Grant: 3UM1CA186644-06S1

North American Star Consortium

National Institutes of Health

Grant: 3UH2TR001373-01S1

Wee1 and HDAC inhibition in relapsed/refractory AML

National Institutes of Health

Grant: 1S10OD020091-01

Acquisition of a triple quadrupole mass spectrometer for small molecule analysis

National Institutes of Health

Grant: 3P30CA006973-53S2

Regional Oncology Research Center

FWCI

1.73

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10807611/pdf/nihms-1955002.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s00280-023-04511-0.pdf

publisherhttps://link.springer.com/article/10.1007/s00280-023-04511-0/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10807611

Fields of Study

Histone Deacetylase Inhibitors ResearchAcute Myeloid Leukemia ResearchBiochemical and Molecular Research03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansHydroxamic AcidsPyrazolesPyrimidinonesSulfonamidesLeukemia, Myeloid, AcuteMice

Keywords

MedicineDysgeusiaNauseaAdverse effectPharmacologyInternal medicineMucositisToxicityRefractory (planetary science)Myeloid leukemiaNeutropeniaPharmacokineticsGastroenterologyOncologyPopulationAcute leukemiaMyelodysplastic syndromeBelinostatPhase 1 Clinical TrialAdavosertibMiceLeukemia, Myeloid, AcuteSulfonamidesHumansAnimalsPyrazolesPyrimidinonesHydroxamic Acids

Sustainable Development Goals

SDG 0: Good health and well-being

Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

FAIR Checklist

Authors (12)

Funding (17 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)